Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
States have an important role in ensuring food safety and healthy food practices.
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
To address the preventive & primary healthcare delivery gaps in India
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Subscribe To Our Newsletter & Stay Updated
